# A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

> **NCT06113302** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT06113302
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2026-06-02
- **Final completion:** 2026-06-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06113302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06113302, "A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06113302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*